Autosomal Dominant Tubulointerstitial Kidney Disease: An Emerging Cause of Genetic CKD

Laura Econimo1, Celine Schaeffer2, Letizia Zeni1, Roberta Cortinovis1, Federico Alberici1, Luca Rampoldi2, Francesco Scolari1 and Claudia Izzi1,3

1Division of Nephrology and Dialysis, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia and ASST-Spedali Civili of Brescia, Italy; 2Molecular Genetics of Renal Disorders, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy; and 3Medical Genetics Clinic, Department of Obstetrics and Gynaecology, ASST-Spedali Civili, Brescia, Italy

Autosomal dominant tubulointerstitial kidney disease (ADTKD) is a rare inherited disorder characterized by progressive loss of kidney function, nonsignificant urinalysis and tubulointerstitial fibrosis. ADTKD progresses to end stage renal disease (ESRD) in adulthood. The classification of ADTKD is an evolving concept and the agreement is now that, due to the overlap in terms of phenotype characteristics, this should be based on the involved gene. The umbrella term ADTKD therefore includes different conditions as follows: ADTKD-UMOD, ADKT-MUC1, ADTK-REN, and ADTK-HNF1B, with ADTKD-SEC61A1 and ADTKD-DNAJB11 as a further rare and atypical diagnosis recently described.

The employment of next-generation sequencing (NGS) as a diagnostic tool in patients with familial kidney disease has improved the diagnostic accuracy in this field with ADTKD now being considered the third genetic cause of renal disease worldwide after autosomal dominant polycystic kidney disease (ADPKD) and Alport syndrome.

On average, the disease pathogenesis is similar across the different subtypes, With the exception of HNF1B, the different mutated genes give rise to misfolded proteins leading to cellular stress and cytotoxicity. Research is now focused in better defining the underlying mechanism of fibrosis to guide therapeutic interventions.

The aim of this review is to discuss how the knowledge of ADTKD has evolved in the last decades, with emphasis on the clinical features, molecular diagnosis, and pathogenic aspects of the different diseases included under the ADTKD term.

Kidney Int Rep (2022) 7, 2332–2344; https://doi.org/10.1016/j.ekir.2022.08.012

KEYWORDS: ADTKD; DNAJB11; HNF1B; MUC1; REN; UMOD

© 2022 Published by Elsevier, Inc., on behalf of the International Society of Nephrology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Of note, the genetic cause of MCKD1 remained unidentified for a long time and only in 2013 were variants of the MUC1 gene detected as a cause for this disease. To add complexity, a wide genetic heterogeneity of FJHN was subsequently discovered as follows: FJHN2, caused by pathogenic variant in the REN gene; FJHN3, mapped to chromosome 2p22.1-p21 (gene not yet identified); and FJHN4 caused by pathogenic variants in the SEC61A1 gene. Finally, an atypical form of FJHN, associated with renal cysts and diabetes, was found to be caused by pathogenic variant in the HNF1B gene.

Because the common feature of these diseases is tubulointerstitial fibrosis, the unifying definition of ADTKD was proposed. In 2015, a subclassification, according to the detected pathogenic variants in the 4 known causative genes (ADTKD-UMOD, ADTKD-MUC1, ADTKD-REN, ADTKD-HNF1B) was adopted, following a consensus KDIGO conference. After this KDIGO conference, other rare ADTKD genes were identified, namely SEC61A1 and DNAJB11, the latter being associated with a phenotype overlapping ADPKD and ADTKD. Because pathogenic variants in UMOD, MUC1, REN, and HNF1B are detected only in about 50% of the ADTKD probands, other causative genes are yet to be identified; for such cases the term ADTKD-not otherwise specified for “not otherwise specified” was proposed.

For an uncommon disease such as ADTKD, the prevalence is difficult to establish because cases are few and hard to diagnose. Recent new molecular diagnostic approaches with NGS analysis and large international cohort studies led to the identifying new cases of ADTKD. It is estimated that ADTKD-UMOD alone accounts for 3% of genetic cause of renal disease worldwide, ranking as the third genetic cause of nephropathy after ADPKD and Alport syndrome. Moreover, ADTKD-MUC1 is the second most prevalent ADTKD form, thus, considering the difficulty of identifying MUC1 pathogenic variants through genetic testing because it escapes NGS techniques, total ADTKD prevalence could be higher.

In this review we will discuss genetic, clinical features and disease mechanisms of the following 6 different forms of ADTKD, further classified according to the underlying genetic defect: ADTKD-UMOD, ADTKD-MUC1, ADTKD-REN, ADTKD-HNF1B, ADTKD-SEC61A1, and ADTKD-DNAJB11. Common and disease-specific clinical features of known ADTKD forms are illustrated in Figure 1 and 2.

**ADTKD-UMOD**

Previously known as FJHN1 or MCKD2, ADTKD-UMOD (OMIM #162000) is the most frequent form of ADTKD. A nation-wide epidemiologic survey conducted in Austria revealed a prevalence of 1.7 cases of ADTKD-UMOD per million in the population. In a recent large exome-sequencing study, 0.3% of patients with chronic kidney disease (CKD) were found to have ADTKD-UMOD disease. Recently, data from 2 large ADTKD registries, including 726 ADTKD patients suggested that ADTKD-UMOD is the most frequent subtype of ADTKD, showing a prevalence of 37%.

![Figure 1. Shared and hallmark clinical features of the different types of ADTKD. ADTKD, autosomal dominant tubulointerstitial kidney disease; CAKUT, congenital anomalies of the kidney and urinary tract; CKD, chronic kidney disease; ESRD, end stage renal disease; NDD, neuro-developmental delay; yo, year.](image-url)

**Figure 1.** Shared and hallmark clinical features of the different types of ADTKD. ADTKD, autosomal dominant tubulointerstitial kidney disease; CAKUT, congenital anomalies of the kidney and urinary tract; CKD, chronic kidney disease; ESRD, end stage renal disease; NDD, neuro-developmental delay; yo, year.
Clinical Manifestations
ADTKD-UMOD patients usually develop slowly progressive asymptomatic elevations of serum creatinine concentration between the second and the fourth decade of life. Urinalysis is negative with bland urinary sediment and mild proteinuria. A defective urinary concentration is present although not clinically relevant. Histology is usually unspecific and may mimic focal segmental glomerulosclerosis; electron microscopy may reveal uromodulin accumulation as large intracellular deposits (fibrillar or amorphous material) in the endoplasmic reticulum (ER) of the thick ascending limb (TAL) of Henle’s loop (Figure 3). Ultrasonography may reveal renal cysts whereby the kidney size is usually normal but declines with disease progression. Heterogeneity in ESRD age of onset has been reported. In a recent large international study, the median age at onset was 47 years (range 18-87) and women had significantly better renal survival. In the ADTKD cohort, including the European and USA ADTKD registries, the median age at onset of ESRD was 54 years (range 25 to >70 years); prognosis was confirmed to be worse in men with a more rapid progression to ESRD. Hyperuricemia is frequent (70–80% of patients) and usually precedes CKD. Gout develops at a median age of 27 years and more frequently affects men, with a prevalence variable from 24% to >70% of patients.

Diagnosis
The definitive diagnosis can be established by genetic testing showing a heterozygous pathogenic variant in UMOD gene (11 exons). In the past, molecular testing approach included single-gene testing performed by Sanger sequencing. Recently, NGS analysis of a multi-gene panel, including UMOD and other genes of interest have been more frequently employed (Table 1). To date, >130 pathogenic variants in UMOD gene have been described with the most frequently reported being missense changes, clustered in exons 3 and 4, resulting in the replacement of cysteine residues and leading to misfolding of the uromodulin protein (Table 1).

Disease Mechanism
UMOD is a kidney-specific protein, produced by the epithelial cells in the TAL of Henle and by the initial part of the distal convoluted tubule. UMOD plays a key role in water homeostasis. In the tubule, UMOD polymerizes into gel-like structures contributing to water permeability of TAL; moreover, UMOD regulates the activity of the renal outer medullary potassium channel and of the sodium-potassium-chloride co-transporter. Of note, by inhibiting calcium oxalate crystallization, UMOD exerts a protective role against nephrolithiasis and its biochemical properties make it a candidate for being a host defense factor involved in
clearing bacteria from the urinary tract. UMOD seems also to have an immunomodulatory function, trapping pro-inflammatory molecules and modulating neutrophilic migration in the setting of acute kidney injury. Finally, recent studies suggest that serum and urinary levels of UMOD can be considered surrogate markers of kidney function and nephron mass.

UMOD disease-causing variants affect the biosynthesis of the protein, leading to protein misfolding, aberrant intracellular trafficking and ER retention of the mutant protein, supporting the designation of ADTKD-UMOD as a storage disease. In renal biopsy of ADTKD-UMOD patients UMOD accumulates in large intracellular aggregates that colocalize with ER markers, leading to expansion of ER stacks. Intracellular retention is consistent with the reduced level of uromodulin in urine and blood of ADTKD-UMOD patients. Several in vitro and in vivo models of mutant uromodulin expression have clearly established ER retention of mutant uromodulin as the primary effect of UMOD pathogenic variants. In particular, several models reported the induction of ER stress and of the unfolded protein response (UPR), a cellular response aimed at restoring ER homeostasis. The accumulation of the misfolded protein leading to chronic ER stress of TAL cells is likely to be at the basis of the observed defect in mitochondria biogenesis and function and of a maladaptive suppression of autophagy.

In all mouse models of ADTKD-UMOD, ER retention and aggregation of mutant uromodulin is followed by progressive renal damage, i.e., tubulointerstitial fibrosis with inflammatory cell infiltration and tubule dilation, urinary concentrating defect, and renal failure, hence recapitulating the clinicopathologic features of ADTKD-UMOD. This phenotype is not reproduced in UMOD-knockout mice establishing the mechanism of action of UMOD pathogenic variants as mostly a gain-of-toxic function. This effect could be exerted intracellularly due to ER retention but also extracellularly. Mutant uromodulin excretion was indeed detected in patients carrying uromodulin pathogenic variants and the presence of mutant uromodulin on the plasma membrane was shown to interfere with the polymerization of the wild-type isoform through formation of large extracellular aggregates. Nevertheless, a loss-of-function effect

Table 1. Genetics and molecular diagnosis of ADTKD

| Gene | OMIM#   | Chr | Exons | Pathogenic variants                                                                 | Molecular analysis methods                        |
|------|---------|-----|-------|-------------------------------------------------------------------------------------|---------------------------------------------------|
| UMOD | 191845  | 16p | 12.3  | Single nucleotide variants: -95.3% missense pathogenic variants -89.6% located in exons 3 | Sanger sequencing and/or NGS analysis              |
| MUC1 | 158340  | 1q  | 22    | Mostly a cytosine duplication within a domain of VNTR leading to a frameshift pathogenic variant | Mass spectrometry or SNaPshot mini-sequencing     |
| REN  | 179820  | 1q  | 32.1  | Single nucleotide variants in the prosegment, signal peptide and mature peptide      | Sanger sequencing and/or NGS analysis              |
| HNF1B| 189907  | 17q | 12    | 42% sequence substitutions 49% whole gene deletions 6% duplications                  | Sanger sequencing and/or NGS and MLPA or copy number variation analysis |
| SEC61A1| 617056 | 3q  | 21.3  | Single nucleotide variants                                                          | Sanger sequencing and/or NGS analysis              |
| DNAJB11| 618061| 3q  | 27.3  | Single nucleotide variants                                                          | Sanger sequencing and/or NGS analysis              |

ADTKD, autosomal dominant tubulointerstitial kidney disease; Chr, chromosome; MLPA, Multiplex Ligation-dependent Probe Amplification; NGS, next-generation sequencing; VNTR, variable number of tandem repeats.
possibly secondary to loss of the integrity of TAL cells, may determine a defect in urinary concentration and a reduction in sodium reabsorption, leading to hypovolemia. The volume depletion can subsequently increase the reabsorption of uric acid in the proximal tubule, causing a lower fractional excretion of urate and hyperuricaemia, as observed in UMOD knockout mice.45

Though the primary effect of UMOD pathogenic variants (ER retention and ER stress) has been largely documented, its downstream effects are less known. Inflammation is likely to play an important role in disease onset because inflammatory markers have been recognized in ADTKD mouse model at very early stage well before the induction of fibrosis and renal damage.47

Onset and progression of the disease in mouse models depend on the pathogenic variant type and its allelic status.40 In humans, there is high inter familial and intrafamilial variability of clinical parameters, such as the age at ESRD, making it difficult to establish a clear genotype-phenotype correlation. Nevertheless, gene dosage effect seems to be present also in humans, because the few individuals carrying UMOD pathogenic variants in homozygosity present a more severe disease.48 Moreover, a recent study analyzing the clinical characteristics associated with 125 UMOD pathogenic variants identified the male sex and the severity of trafficking defect of mutant uromodulin (scored in cell models) as risk factors for earlier age at ESRD.24

**Management**

No specific therapy is available for ADTKD-UMOD. Treatment includes management of gout and of CKD. No conclusive evidence suggests a benefit on CKD progression of allopurinol, which can prevent gouty arthritis attacks. The management of hypertension, hyperphosphatemia, anemia, and ESRD is similar to that proposed to patients with other causes of CKD. ADTKD patients are good candidates for renal transplantation, because the genetic disease does not recur.1,2 Only few trials of pre-clinical therapeutic interventions have been reported so far. Interestingly, disease progression was reduced in a knock-in mouse model of ADTKD-UMOD after anti-inflammatory treatment with TNFR:Fc, a tumor necrosis factor-α inhibitor,41 supporting a role for inflammation in disease onset and progression. More recently, BRD4780, a small molecule first identified for ADTKD-MUC1 treatment (see below), was shown to induce mutant uromodulin degradation in cellular models.49 The effectiveness of this molecule still needs to be tested in vivo.

**ADTKD-MUC1**

The true prevalence of ADTKD-MUC1, previously known as MCKD1, is difficult to estimate, as pathogenic variants in MUC1, not detected by NGS analysis, require specialized genetic testing not routinely performed.2 For these technical difficulties, the disease was mapped in 1998 on chromosome 1q21,8 but the causative gene MUC1 (7 exons) was identified only 15 years later.12 According to the 2 large ADTKD registries from Europe and United States, ADTKD-MUC1 is the second most frequent form of ADTKD, representing 35% of UMOD-negative families, with an estimated overall prevalence of 21%.20

**Clinical Manifestations**

Main clinical features are indistinguishable from ADTKD-UMOD, including slowly progressive CKD, nonsignificant urinalysis, dominant inheritance, and hyperuricemia or gout.1,2 In the first large study performed, Bleyer et al. Described a variable age of onset of ESRD (mean age 45 years; range 16–80 years) and a rapid progression to dialysis in the third decade of life.20 In the cohort derived from European and USA ADTKD registries, the renal disease appeared to be more severe in patients with ADTKD-MUC1 when compared with ADTKD-UMOD, with higher prevalence of ESRD (58% vs. 44%) and earlier onset of ESRD (36 years vs. 46 years). In addition, gout was less frequent in ADTKD-MUC1 (26%) compared with ADTKD-UMOD (79%).20

**Diagnosis**

The diagnosis of ADTKD-MUC1 is based on the identification of a heterozygous MUC1 pathogenic variant. The molecular testing for ADTKD-MUC1 is challenging because the mutational hotspot is a large variable number of tandem repeats of MUC1 gene that escapes detection by standard sequencing techniques.12 The most common pathogenic variant is a cytosine duplication within a stretch of 7 cytosines within 1 unit of variable number of tandem repeats sequence. Other mutations involve the addition of a guanosine residue or loss of 2 cytosine residues. All disease-causing variants result in the same frameshift (fs) change leading to the synthesis of a frameshifted protein that is prematurely terminate (MUC1-fs). MUC1 pathogenic variants are not identified using gene panels or whole exome sequencing and alternative methods of detection (mass spectrometry or SnaPshot mini-sequencing) have been developed (Table 1).12,51-53 Unfortunately, current MUC1 testing techniques are able to identify only the most frequent pathogenic variant that involves cytosine but not the others. To our knowledge, MUC1 testing is available in few laboratories in Europe and US.
(Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States; First Faculty of Medicine, Charles University, Prague, Czech Republic; Fundació Puigvert, Barcelona, Spain; and Laboratorio di Biochimica Clinica, Azienda Ospedaliera Universitaria di Novara, Italy).

An alternative nongenetic disease diagnostic tool has been suggested, using immunohistochemistry for the specific detection of the MUC1-fs peptide on kidney biopsy specimens or on urinary exfoliated cells of patients. The immunodetection of MUC1-fs could be applicable to selected patients for molecular diagnosis and can provide diagnosis in patients in whom the pathogenic variant is different from the cytosine insertion as well as in renal transplant patients, because mucin 1 is also produced by the bladder cells of transplant recipient.49–55

Disease Mechanism

The MUC1 gene encodes mucin1, a transmembrane glycoprotein expressed on the apical surface of many epithelial cells, including breast, lung, intestine, and kidney, providing a protective barrier.5 Mucin1 is also involved in cellular signaling.2 In the kidney, mucin 1 is expressed on TAL, distal convoluted tubule, and collecting duct.2,56 The abnormal MUC1-fs neo-peptide accumulates in the cytoplasm of tubular epithelial cells, where it accelerates cell death, determining tubulointerstitial fibrosis and CKD.2,57 All MUC1 pathogenic variants lead to the same aberrant protein, suggesting that MUC1-fs protein is central in the pathogenesis. Because knockout Muc1 mice are characterized by the absence of a developmental phenotype,2,58 ADTKD-MUC1 is likely caused by a gain-of-function effect of pathogenic variants. How the abnormal MUC1-fs protein causes progressive tubulointerstitial renal damage is poorly understood, as well as why the pathogenic variant produces an abnormal phenotype only in the kidney, despite its presence in several tissues. An important step toward the elucidation of the mechanisms of pathogenesis in ADTK—MUC1 was recently achieved in in vitro and in vivo models of MUC1-fs expression, demonstrating that MUC1-fs accumulates intracellularly in the ER-Golgi intermediate compartment, leading to activation of the ATF6 branch of the unfolded protein response. Through small molecule screening, a new lead molecule, BRD4780, was identified, able to selectively bind TMED9 receptor, which has a key role in the retention of MUC1-fs in the ER-Golgi intermediate compartment. The binding BRD4780-TMED9 releases MUC1-fs that is re-routed toward the lysosome for degradation, thus clearing MUC1-fs from the cells.49

Management

No specific therapy is available for ADTKD-MUC1. The newly identified lead molecule BRD4780 which, by selectively binding TMED9, induces the removal of mutant protein MUC1-fs could represent a potential approach for ADTKD-MUC1. Importantly, this molecule was found to be effective (at least in vitro) in other toxic proteinopathies characterized by intracellular retention of misfolded proteins, such as ADTKD-UMOD.49

ADTKD-REN

ADTKD-REN, previously known as FJHN2, is due to disease-causing variants in the REN gene (10 exons, chromosome 1).2,59 The human renin precursor is synthesized in the juxtaglomerular cells in the juxtaglomerular apparatus of the kidney as a 406 amino acid pre-REN, composed of a 23 amino acid N-terminal signal peptide, a 43 amino acid prosegment, and a 340 amino acid mature renin peptide. Renin has a key role in the renin-angiotensin-aldosterone system, which exhibits multiple biological functions, including vascular tone modulation, renal sodium and potassium handling, erythropoiesis, and cardiac hypertrophy.60 ADTKD-REN is a very rare condition because so far, 30 families, including 111 affected individuals have been described.61

Clinical Manifestations

ADTKD-REN is a condition with onset in childhood; rarely, REN pathogenic variants can cause an adult, milder form of the disease.61,62 Most clinical, laboratory, ultrasonographic, and histologic findings are nonspecific, except for a decreased immunostaining for renin in the juxtaglomerular apparatus.2 Nevertheless, some features appear to be relatively characteristic, being attributed to a decreased secretion of renin. Due to low renin and aldosterone levels, ADTKD-REN patients may experience some degrees of hypotension and hyperkalemia.60–62 Children are at increased risk of acute kidney injury, particularly in case of volume depletion and use of NSAIDs, as a consequence of the combination of low renin activity, volume depletion, and prostaglandin inhibition.2,61 Recently, a large international retrospective cohort provided clinical and genetic data on 111 individuals from 30 families with heterozygous REN disease-causing variants; 69 patients harbored a REN pathogenic variant in the signal peptide region; 27 in the prosegment; and 15 in the mature renin peptide. Differences in the severity of the clinical manifestation of the disease were observed according to the position of the pathogenic variant. Patients harboring the pathogenic variant in the signal peptide and prosegment region were most severely
affected, with clinical onset during childhood of kidney failure and anemia. In these groups most patients have estimated glomerular filtration rate <60 ml/min per 1.73 m² at earliest presentation, suggesting that decreased kidney function is present at birth and therefore can be noted in the first weeks of life. Despite early onset, childhood and adolescence renal function tended to be relatively stable, although decreased. The presence of hypoproliferative anemia is thought to be secondary to low erythropoietin levels. Interestingly, anemia resolves as the child enters adolescence, probably due to the rise in sex steroid production enhancing erythropoietin production. Patients with REN disease-causing variants in the mature peptide showed a milder course of the disease with gout in early adulthood or CKD later in life. Differences in the median age at ESRD were also observed among the 3 groups of patients, with patients with pathogenic variants in the signal peptide and prosegment reaching ESRD earlier (57 years and 62 years, respectively) than the patients with pathogenic variants located in the mature protein (68 years).

**Diagnosis**

Findings suggestive of ADTKD-REN are very early onset of CKD, which can be found at 3 or 4 years of age or even earlier; hypoproliferative anemia beginning early in life (1 year or 3 years) and resolving during adolescence; and hyperuricemia and gout, usually in the second decade of life. Urinalysis reveals a bland urinary sediment and low degree proteinuria. Renal ultrasonography is nondiagnostic, showing normal or small kidneys. Plasma renin and plasma aldosterone are low; serum potassium is mildly elevated. Though renal biopsy may show nonspecific features of tubulointerstitial fibrosis, immunostaining for renin in the granular cells of the juxtaglomerular apparatus may be decreased. The final diagnosis may be established by genetic testing. Because pathogenic REN disease-causing variants are mostly single nucleotide variants, standard methods of genetic testing may be used, including both Sanger and NGS sequencing (Table 1).

To date, a total of 16 disease-causing variants have been identified as follows: 8 (50% of total pathogenic variants, 70% of the families) map in the signal peptide; 3 in the prosegment (19% of total pathogenic variants, 13% of the families); and 5 (31% of total pathogenic variants, 17% of the families) in the mature part of renin.

**Disease Mechanism**

Renin is synthesized as pre-prorenin that is translocated into the ER where it is processed to prorenin by cleavage of the signal peptide. In addition to the signal peptide (which directs the insertion of the nascent pre-prorenin into the translocation channel in the ER), pre-prorenin contains a prosegment, located after the signal peptide that assists in protein folding and the mature renin peptide. Homozygosity or compound heterozygosity for loss-of-function REN pathogenic variants causing complete loss of renin synthesis were first described in 2005 in autosomal recessive renal tubular dysgenesis, a very rare condition leading to perinatal mortality. In 2009, Zivná et al. reported heterozygous dominant pathogenic variants in the REN gene, resulting in reduced prorenin and renin biosynthesis and secretion. In this setting, production of wild-type renin occurs via 1 allele, enabling kidney development but causing symptoms of low renin activity, such as mild hypertensive state, hyperkalemia, anemia and renal tubulointerstitial fibrosis. The molecular mechanisms of renal fibrosis are not fully understood. Pathogenic variants affecting the signal sequence are associated with an impaired co-translational insertion in the ER of the mutated pre-prorenin, which is aberrantly located in the cytoplasm. Mutant renin due to pathogenic variants affecting the mature renin is retained in the ER, likely due to protein misfolding, and induces ER stress and activation of the unfolded protein response in vitro that may possibly lead in vivo to accelerated cell death, tubulointerstitial fibrosis, and progressive loss of kidney function. REN pathogenic variants in the prosegment led to deposition of prorenin and renin in the ER-Golgi intermediate compartment, decreasing prorenin secretion.

**Management**

In ADTKD-REN patients, in addition to the management of progressive CKD and gout, anemia, hypotension and hyperkalemia can be treated with erythropoiesis-stimulating agents and fludrocortisone. Moreover, considering that part of renin pathogenic variants lead to prorenin accumulation in the early secretory pathway, similarly to MUC1-fs, a potential role for BRD4780 in this context may have a rational.

**ADTKD-HNF1B**

HNF1B gene is a developmental gene located on chromosome 17q12, coding for hepatocyte nuclear factor 1 homeobox B protein, which is required for tissue specific gene expression in the epithelial cells of many organs, including kidney, pancreas, liver, and genitourinary tract. Heterozygous pathogenic variants of HNF1B gene are responsible for a dominant inherited disease with several renal and extrarenal phenotypes as exocrine pancreatic failure, pancreatic hypoplasia, fluctuating liver test abnormality, early-onset gout, and genital tract malformations.
umbrella term used to include the various kidney phenotypes of the disease, ranging from congenital anomalies of the kidney and urinary tract, tubular transport abnormalities, cystic renal disease and ADTKD.65-69

**Clinical Manifestations**

HNF1B-disease is a condition with renal phenotype varying according to the age at recognition. The prevalence of HNF1B pathogenic variants in children with structurally abnormal kidneys is approximately 20%. In the fetus, the most frequent phenotype is hyper-echogenic kidneys.68 In childhood, HNF1B-nephropathy usually shows renal cystic hypoplasia, congenital anomalies of the kidney and urinary tract and tubular transport disorders (hypomagnesemia, hypokalemia).68,70 In the adult, the renal disease manifests as ADTKD, associated with hyperuricemia and gout, and varying degrees of renal impairment, from mild slow progressive CKD to ESRD.68,69 The renal phenotype described in adulthood is very similar to the one observed in patients with ADTKD-UMOD, ADTKD-MUC1, and ADTKD-REN. Nevertheless, whereas the clinical manifestations of diseases caused by pathogenic variants in UMOD, MUC1, and REN are usually confined to the kidney, HNF1B pathogenic variants can result in variable and associated renal manifestations, including congenital anomalies of the kidney and urinary tract, renal cysts, hypomagnesemia and hypokalemia. Therefore, some authors suggested to confine the term ADTKD only to those rare HNF1B-related cases in which tubule-interstitial fibrosis is the leading renal manifestation.1 A large spectrum of extrarenal manifestations can be associated, such as MODY5, pancreatic hypoplasia, liver test abnormalities, and genital tract malformations.65-68 Neurodevelopmental disorders have also been described, particularly in patients with chromosome 17q12 deletion encompassing HNF1B gene.2,67,68

Recently the mnemonic MAGIC LUCID has been suggested to summarize the possible clinical manifestations of HNF1B disease, including renal and extrarenal manifestations (M= Hypomagnesemia; A= Autosomal dominant; G= Genital tract abnormalities, including bicornuate uterus, absent uterus, vaginal hypoplasia; I= Incomplete penetrance; C= Cysts of the kidney and other structural abnormalities, including multicystic kidneys, fetal bilateral hyperechogenic kidneys, kidney agenesis, and hypoplastic kidneys; L= Liver test abnormalities; U= Uric acid elevation; I= Inherited; D= Diabetes and pancreatic abnormalities.)71

**Diagnosis**

Clinical diagnosis of HNF1B-nephropathy is challenging, because the disease may mimic a variety of renal disorders. The presence of extrarenal manifestations is an important tool for early diagnosis. Although the association of MODY with a heterogenous clinical kidney disease is the core phenotype of HFN1B-associated disease, a patient can present only 1 of the possible clinical features. Moreover, it is possible to observe in the same family a different clinical characteristic for each member. The extreme variability, also intrafamilial, and incomplete penetrance of clinical features makes diagnosis of HNF1B-disease even more challenging.2,65-69 For the final molecular diagnosis, conventional sequence analysis for point pathogenic variants should be combined with Multiplex Ligation-dependent Probe Amplification or copy number variation analysis, to identify whole gene deletion, which is the molecular defect identified in 40% to 50% of patients, occurring also in the context of the 17q12 Recurrent Deletion Syndrome.2,67 In the remaining cases, point pathogenic variant can be detected, 50% being missense (Table 1). Interestingly, de novo pathogenic variants are up to 30% to 50% of cases; thus, the presence or not of a positive family history is less significant for diagnosis than in other forms of ADTKD.2,67

**Mechanisms of Disease**

HNF1B coordinates transcriptional networks regulating nephrogenesis, renal tubular ion transport, and transcription of numerous cystic disease genes (PKHD1, PKD2, UMOD, and GLIS2).2,67,72 This may explain, in patients with HNF1B gene anomalies, the frequent occurrence of congenital anomalies of the kidney and urinary tract, renal cystic disease, hypomagnesemia and hypokalemia. The mechanism whereby mutated HNF1B leads to renal fibrosis is not fully understood.73 However, recent data showed that HNF1B is implicated in epithelial–mesenchymal transition,74 a process by which epithelial cells acquire mesenchymal characteristics. Epithelial–mesenchymal transition is essential for tissue regeneration and, when sustained, is associated with fibro-genesis. Because 50% of ADTKD–HNF1B patients are heterozygous for full gene deletion, and the remaining have truncating or missense pathogenic variants,2 ADTKD–HNF1B phenotype is likely to be caused by haplo-insufficiency.

**Management**

In ADTKD–HNF1B patients, management should pay attention to extrarenal manifestations, including pancreatic dysfunction, genital tract malformations, and neuropsychiatric symptoms. Basic knowledge on how to modulate HNF1B expression or activity is still very limited. Strategies aiming at increasing wild-type
allele expression or activity could be very valuable in view of therapeutic intervention, because nowadays no specific therapy is available.

ADTKD-SEC61A1

ADTKD-SEC61A1 (previously FJHN4) is a very rare disease, being reported in 2 families. Two additional families with SEC61A1 disease-causing variants have also been reported with primary antibody deficiency and unknown renal phenotype.

Clinical Manifestations

In 2016, Bolar et al. described 2 ADTKD families harboring missense pathogenic variants in SEC61A1 gene, disrupting the function of the translocon pore. The first family presented slow progressive ADTKD, anemia, hyperuricemia, and early gout. Renal ultrasound revealed small cystic dysplastic kidneys. Renal biopsy showed multiple foci of tubulointerstitial lesions and glomerular sclerosis. The affected members of the second ADTKD-SEC61A1 family presented CKD, anemia, neutropenia, and early gout. In 2018, Schubert et al. described 2 families with heterozygous SEC61A1 pathogenic variants showing hypergammaglobulinemia and early-onset respiratory tract infections; the renal phenotype was not provided.

Diagnosis

ADTKD-SEC61A1 should be considered when, in addition to the presence of ADTKD, anemia, neutropenia, and recurrent respiratory tract infections are observed. The confirmatory diagnosis must be obtained by the demonstration of the underlying genetic defect of SEC61A1 gene, using Sanger or NGS sequencing (Table 1).

Mechanism of Disease

SEC61A1 gene (chromosome 3q21.3) encodes the subunit alpha 1 of the heterotrimeric protein-conducting channel SEC61, also, including beta (SEC61B) and gamma (SEC61G) subunits. SEC61A1 is the major component of the mammalian translocon, a complex needed to transport newly synthesized secretory proteins into the ER. The pathogenic variants affect the selectivity and permeability of the pore of the translocon channel, leading to SEC61-channelopathy. In vitro studies showed that altered structural properties of SEC61A1 induced by pathogenic variants cause aggregation of the mutated SEC61A1 in the ER and misrouting to the Golgi apparatus, leading to alterations in post-translational modifications and folding of various secretory and transmembrane proteins, including uromodulin, mucin1, and renin. A recent study demonstrated that ADTKD-SEC61A1 mutations lead to a signal peptide dependent impairment of protein ER translocation, renin being one of the defective substrates, and to a reduction of regulatory calcium transporters (i.e. Orai1 and SERCA2) interacting with the SEC61 complex. These events may induce ER stress (as in ADTKD-REN, ADTKD-UMOD, and ADTKD-MUC1), leading to apoptosis and ultimately to interstitial fibrosis.

Finally, animal studies (zebrafish) suggested that the SEC61 complex and its translocon function are necessary for normal renal development. Of note, a similar phenotype consisting of pronephros development defect was also observed on expression of renin mutants associated with ADTKD. Taken together, these data expand the genetic spectrum of the tubulointerstitial kidney disorders, allowing to include pathogenic variants of SEC61A1 (determining protein translocation defects across the ER membrane) as a possible cause of ADTKD.

Management

No specific therapy is available for ADTKD-SEC61A1. Recently, it has been shown that treatment with the small molecule sodium phenylbutyrate (an US Food and Drug Administration approved drug for treatment of urea cycle disorders) may reverse the impairment of renin transport in ADTKD-SEC61A1, suggesting that phenylbutyrate could be a potential early therapy for ADTKD-SEC61A1.

ADTKD-DNAJB11

ADTKD-DNAJB11 is an atypical and very rare cause of tubulointerstitial kidney diseases. Recently 7 families were reported with 5 different heterozygous pathogenic variants in DNAJB11 gene. The transmission pattern is consistent with autosomal dominant inheritance. Renal phenotype in affected family members mostly overlap clinical features of ADPKD with bilateral small renal cysts, slightly enlarged kidneys, liver cysts, and slowly progressive renal failure with ESRD in the sixth to seventh decade. In some patients, renal histologic examination revealed tubulointerstitial fibrosis and in 1 family at least 3 patients showed gout. Thus, the authors suggested a phenotype partly overlapping with ADPKD and ADTKD. Due to overlapping clinical phenotype with cystic kidney diseases, the diagnosis could be established only with genetic analysis confirming the presence of pathogenic heterozygous variant in DNAJB11 gene, using Sanger or NGS sequencing (Table 1).

Mechanism of Disease

The DNAJB11 gene encodes a cofactor of GRP78/BiP, a major ER chaperone regulating folding, trafficking and
degradation of secreted and membrane protein, thus playing a major role in ER homeostasis.

Evidence linking DNAJB11 with ADPKD and ADTKD have been found. Studies of DNAJB11-null human renal cortical tubular epithelial cells showed a defective maturation process of the PKD1 protein. Moreover, histologic analysis of renal samples from affected patients revealed abnormal intracellular retention of uromodulin and mucin1 linking DNAJB11 disease with pathogenic mechanism of tubulointerstitial disease.78

**Genetic Counseling**

ADTKD is a Mendelian autosomal dominant disorder where at-risk individuals have a 50% chance of inheriting the disease. Genetic counseling should be offered to all patients to discuss potential risks to offspring, reproductive options, possible genotype-phenotype correlation (i.e. location of pathogenic variants in REN: in the signal peptide and prosegment vs. mature protein) and challenging intrafamilial phenotypic variability mainly for HNF1B disease.61,71

Genetic testing is currently the only way to confirm ADTKD and its subtypes. The most widely shared genetic testing strategy consists of a stepwise approach as follows: first, NGS analysis of a gene panel, including ADTKD genes (UMOD, REN, HNF1B, SEC61A11, DNAJB11) and Multiplex Ligation-dependent Probe Amplification analysis for HNF1B gene, in case of negative result MUC1 analysis if available should be performed as last step.2,18 It is important to explain during genetic counseling that a negative result does not exclude the diagnosis of ADTKD, because rare variants could be missed with conventional analysis and not all ADTKD genes have yet been identified.

In all confirmed genetic cases, at-risk adult family members, even if apparently healthy, can exclude or confirm the presence of the disease through genetic testing. Genetic screening should be mandatory for family members who wish to donate a kidney.1 In young adults with childhood onset diseases (i.e. HNF1B disease) it is appropriate to inform them that the knowledge of causative gene variant may allow preimplantation genetic testing.

ADTKD-UMOD and ADTKD-MUC1 become symptomatic in adult age, thus presymptomatic genetic screening in minors is not generally recommended. Instead, presymptomatic screening of at-risk children should be evaluated in families with pathogenic variants in REN, HNF1B, and SEC61A1 that could be associated with childhood onset disease.71

**Conclusion**

ADTKD includes at least 6 different genetic forms (ADTKD-UMOD, ADTKD-MUC1, ADTKD-REN, ADTKD-HNF1B, ADTKD-SEC61A1, and ADTKD-DNAJB11) of slowly progressive kidney disease, characterized by tubulointerstitial fibrosis and tubular damage. In the past, due to the bland urinary sediment and the nonspecific features, many patients with ADTKD remained undiagnosed with these diseases being considered extremely rare. With the identification of ADTKD causing genes and
the increasing availability for genetic analysis, a number of new ADTKD families has been identified; recent studies suggest that ADTKD may be the third most common genetic cause of ESRD after ADPKD and Alport syndrome. The identification of ADTKD causing genes also encouraged the exploration of intracellular pathways activated by the encoded protein, revealing that most associated ADTKD gene pathogenic variants effect on the early secretory pathway (Figure 4). Currently, no approved therapeutic option is available for ADTKD, other than kidney replacement therapy when ESRD is established. Because in the most common forms of ADTKD (UMOD, MUC1, and REN) the pathogenesis can be mainly explained by a gain-of-toxic function mechanism, therapies aiming at decreasing mutant protein accumulation may be effective. Alternatively, strategies aimed at increasing expression or activity of the wild-type protein wild-type could be beneficial for ADTKD-SEC61 and ADTKD-HNF1B subtypes for which pathogenesis is mainly related to a loss-of-function mechanism. The recent advances in disease awareness and in the understanding of the disease mechanisms together with the creation of international networks will help clinicians in improving the diagnostic rates, the clinical management, as well as the genetic counseling while allowing the proper management of the disease and the prompt enrolment in new therapeutic protocols.

**DISCLOSURE**

FA declares serving on the advisory boards of AstraZeneca, GSK, Vifor, and Trevere Therapeutics; also declares consultancy fees from Baxter and Otsuka. All the other authors declared no competing interests.

**ACKNOWLEDGMENTS**

LR is supported by the Italian Ministry of Health (RF-2016-02362623) and the Italian Society of Nephrology (SIN) (Adotta un progetto di Ricerca).

**REFERENCES**

1. Eckardt KU, Alper SL, Antignac C, et al. Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management—a KDIGO consensus report. *Kidney Int*. 2015;88:676–683. https://doi.org/10.1038/ki.2015.28

2. Devuyst O, Olinger E, Weber S, et al. Autosomal dominant tubulointerstitial kidney disease. *Nat Rev Dis Primers*. 2019;5:1–20. https://doi.org/10.1038/s41572-019-0109-9

3. Smith CH, Graham JB. Congenital medullary cysts of the kidneys with severe refractory anemia. *Am J Dis Child*. 1945;69:369–377.

4. Strauss MB, Sommers SC. Medullary cystic disease and familial juvenile nephronophthisis: clinical and pathological identity. *N Engl J Med*. 1967;277:863–864. https://doi.org/10.1056/NEJM196710192771806

5. Hildebrandt F, Waldherr R, Kutt R, Brandis M. The nephronophthisis complex: clinical and genetic aspects. *Clin Investig*. 1992;70:802–808. https://doi.org/10.1007/BF00180751

6. Konrad M, Saunier S, Heidet L, et al. Large homozygous deletions of the 2q13 region are a major cause of juvenile nephronophthisis. *Hum Mol Genet*. 1996;5:367–371. https://doi.org/10.1093/hmg/5.3.367

7. Srivastava S, Molinari E, Raman S, Sayer JA. Many genes—one disease? Genetics of nephronophthisis (NPHP) and NPHP-associated disorders. *Front Pediatr*. 2018;5:287. https://doi.org/10.3389/fped.2017.00287

8. Christodoulou K, Tsingis M, Stavrour C, et al. Chromosome 1 localization of a gene for autosomal dominant medullary cystic kidney disease. *Hum Mol Genet*. 1998;7:905–911. https://doi.org/10.1093/hmg/7.5.905

9. Scolari F, Puzzer D, Amoroso A, et al. Identification of a new locus for medullary cystic disease, on chromosome 16p12. *Am J Hum Genet*. 1999;64:1655–1660. https://doi.org/10.1086/302414

10. Dahan K, Fuchshuber A, Adamis S, et al. Familial juvenile hyperuricemic nephropathy and autosomal dominant medullary cystic kidney disease type 2: two facets of the same disease? *J Am Soc Nephrol*. 2001;12:2348–2357. https://doi.org/10.1681/ASN.20112112348

11. Hart TC, Gorry MC, Hart PS, et al. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. *J Med Genet*. 2002;39:882–889. https://doi.org/10.1136/jmg.39.12.882

12. Kirby A, Gnrirke A, Jaffe DB, et al. Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1 missed by massively parallel sequencing. *Nat Genet*. 2013;45:299–303. https://doi.org/10.1038/ng.2543

13. Zivná M, Hůlková H, Matignon M, et al. Dominant renin gene mutations associated with early-onset hyperuricemia, anemia, and chronic kidney failure. *Am J Hum Genet*. 2009;85:204–213. https://doi.org/10.1016/j.ajhg.2009.07.010

14. Piret SE, Danoy P, Dahan K, et al. Genome-wide study of familial juvenile hyperuricaemic (gouty) nephropathy (FJHN) indicates a new locus, FJHN3, linked to chromosome 2p22. *Hum Genet*. 2011;129:511–518. https://doi.org/10.1007/s00439-010-0897-1

15. Bolar NA, Golcio Z, Živná M, et al. Heterozygous loss-of-function SEC61A1 mutations cause autosomal-dominant tubulo-interstitial and glomerulocystic kidney disease with anemia. *Am J Hum Genet*. 2016;99:174–187. https://doi.org/10.1016/j.ajhg.2016.05.028

16. Verhave JC, Bech AP, Wetzels JF, Nijenhuis T. Hepatocyte nuclear factor 1β-associated kidney disease: more than renal cysts and diabetes. *J Am Soc Nephrol*. 2016;27:345–353. https://doi.org/10.1681/ASN.2015050544

17. Groopman EE, Marasa M, Cameron-Christie S, et al. Diagnostic utility of exome sequencing for kidney disease. *N Engl J Med*. 2019;380:142–151. https://doi.org/10.1056/NEJMoa1808891

18. Mabillard H, Sayer JA, Olinger E. Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease. *Nephrol Dial Transplant*. 2021. https://doi.org/10.1093/ndt/gfab268. Published online September 14

19. Lhotta K, Piret SE, Kramar R, et al. Epidemiology of uromodulin-associated kidney disease—results from a nation-
wide survey. *Nephron Extra*. 2012;2:147–158. https://doi.org/10.1159/000339102

20. Olinger E, Hofmann P, Kidd K, et al. Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease due to mutations in UMOD and MUC1. *Kidney Int*. 2020;98:717–731. https://doi.org/10.1016/j.kint.2020.04.038

21. Chun J, Wang M, Wilkins MS, et al. Autosomal dominant tubulointerstitial kidney disease–uromodulin misclassified as focal segmental glomerulosclerosis or hereditary glomerular disease. *Kidney Int Rep*. 2020;5:519–529. https://doi.org/10.1016/j.ekir.2019.12.016

22. Scolari F, Caridi G, Rampoldi L, et al. Uromodulin storage disease. *Am J Kidney Dis*. 2004;44:987–999. https://doi.org/10.1053/j.ajkd.2004.08.021

23. Nasr SH, Lucia JP, Gaigano SJ, Markowitz GS, D’Agati VD. Uromodulin storage disease. *Kidney Int*. 2008;73:971–976. https://doi.org/10.1038/sj.ajk.13052679

24. Kidd K, Vylet al P, Schaeffer C, et al. Genetic and clinical predictors of age of ESKD in individuals with autosomal dominant tubulointerstitial kidney disease due to UMOD mutations. *Kidney Int Rep*. 2020;5:1472–1485. https://doi.org/10.1016/j.ekir.2020.06.029

25. Ayasreh N, Bullich G, Miquel R, et al. Autosomal dominant tubulointerstitial kidney disease: clinical presentation of patients with ADTKD-UMOD and ADTKD-MUC1. *Am J Kidney Dis*. 2018;72:411–418. https://doi.org/10.1053/j.ajkd.2018.03.019

26. Bollée G, Dahan K, Flamant M, et al. Phenotype and outcome in hereditary tubulointerstitial nephritis secondary to UMOD mutations. *Clin J Am Soc Nephrol*. 2011;6:2429–2438. https://doi.org/10.2215/CJN.01220111

27. Scolari F, Iizi C, Ghiggi GM. Uromodulin: from monogenic to multifactorial diseases. *Nephrol Dial Transplant*. 2015;30:1250–1256. https://doi.org/10.1093/ndt/gfu300

28. Tokonami N, Takata T, Beyerel J, et al. Uromodulin is expressed in the distal convoluted tubule, where it is critical for regulation of the sodium chloride cotransporter NCC. *Kidney Int*. 2018;94:701–715. https://doi.org/10.1016/j.kint.2018.04.021

29. Renigunta A, Renigunta V, Saritas T, Decher N, Mutig K, Waldegger S. Tamm-Horsfall glycoprotein interacts with renal outer medullary potassium channel ROMK2 and regulates its function. *J Biol Chem*. 2011;286:22224–22235. https://doi.org/10.1074/jbc.M110.149880

30. Mutig K, Kahl T, Saritas T, et al. Activation of the bumetanide-sensitive Na+–K+–2Cl– cotransporter (NKCC2) is facilitated by tamm-Horsfall protein in a chloride-sensitive manner. *J Biol Chem*. 2011;286:30200–30210. https://doi.org/10.1074/jbc.M111.222968

31. Gudbjartsson DF, Holm H, Indridason OS, et al. Association of variants at UMOD with chronic kidney disease and kidney stones—role of age and comorbid diseases. *PLoS Genet*. 2010;6:e1001039. https://doi.org/10.1371/journal.pgen.1001039

32. Bates JM Jr, Raffi HM, Prasadak K, et al. Tamm-Horsfall protein knockout mice are more prone to urinary tract infection Rapid Communication. *Kidney Int*. 2004;65:791–797. https://doi.org/10.1111/j.1523-1755.2004.00452.x

33. Micanovic R, Chitteti BR, Dagher PC, et al. Tamm-Horsfall protein regulates granulopoiesis and systemic neutrophil homeostasis. *J Am Soc Nephrol*. 2015;26:2172–2182. https://doi.org/10.1681/ASN.2014070664

34. El-Achkar TM, Wu XR, Rauchman M, McCracken R, Kiefer S, Dagher PC. Tamm-Horsfall protein protects the kidney from ischemic injury by decreasing inflammation and altering TLR4 expression. *Am J Physiol Ren Physiol*. 2008;295:F534–F544. https://doi.org/10.1152/ajpregu.00830.2008

35. Pivin E, Ponte B, de Seigneur S, et al. Uromodulin and nephron mass. *Clin J Am Soc Nephrol*. 2018;13:1556–1557. https://doi.org/10.2215/CJN.03600318

36. Schaeffer C, Devuyst O, Rampoldi L. Uromodulin: Roles in health and disease. *Annu Rev Physiol*. 2021;83:477–501. https://doi.org/10.1146/annurev-physiol-031620-092817

37. Bleyer AJ, Hart TC, Shihabi Z, Robins V, Hoyer JR. Mutations in the uromodulin gene decrease urinary excretion of tamm-Horsfall protein. *Kidney Int*. 2004;66:974–977. https://doi.org/10.1111/j.1523-1755.2004.00845.x

38. Bernasconi I, Vavassori S, Di Pentima A, et al. Defective intracellular trafficking of uromodulin mutant isoforms. *Traffic*. 2006;7:1567–1579. https://doi.org/10.1111/j.1600-0854.2006.00481.x

39. Bernasconi I, Janas S, Ikehata M, et al. A transgenic mouse model for uromodulin-associated kidney diseases shows specific tubulo-interstitial damage, urinary concentrating deficit and renal failure. *Hum Mol Genet*. 2010;19:2998–3010. https://doi.org/10.1038/hmg/ddq205

40. Kemter E, Prueckl P, Sklenak S, et al. Type of uromodulin mutation and allelic status influence onset and severity of uromodulin-associated kidney disease in mice. *Hum Mol Genet*. 2013;22:4148–4163. https://doi.org/10.1038/hmg.ddt263

41. Johnson BG, Dang LT, Marsh G, et al. Uromodulin p. Cys147Trp mutation drives kidney disease by activating ER stress and apoptosis. *J Clin Invest*. 2017;127:3954–3969. https://doi.org/10.1172/JCI93817

42. Kemter E, Fröhlich T, Arnold GJ, Wolf E, Vanke R. Mitochondrial dysregulation secondary to endoplasmic reticulum stress in autosomal dominant tubulointerstitial kidney disease-UMOD (ADTKD-UMOD). *Sci Rep*. 2017;7:42970. https://doi.org/10.1038/srep42970

43. Schaeffer C, Merella S, Pasqualetto E, Lazarevic D, Rampoldi L. Mutant uromodulin expression leads to altered homeostasis of the endoplasmic reticulum and activates the unfolded protein response. *PLoS One*. 2017;12:e0175970. https://doi.org/10.1371/journal.pone.0175970

44. Piret SE, Olinger E, Reed AAC, et al. A mouse model for inherited renal fibrosis associated with endoplasmic reticulum stress. *Dis Model Mech*. 2017;10:773–786. https://doi.org/10.1242/dmm.029488

45. Raffi H, Bates JM, Laszik Z, Kumar S. Tamm-Horsfall protein knockout mice do not develop medullary cystic kidney disease. *Kidney Int*. 2006;69:1914–1915. https://doi.org/10.1038/sj.ki.5000411

46. Schaeffer C, Cattaneo A, Trudu M, et al. Urinary secretion and extracellular aggregation of mutant uromodulin isoforms. *Kidney Int*. 2012;81:769–778. https://doi.org/10.1038/ki.2011.456

47. Trudu M, Schaeffer C, Riba M, et al. Early involvement of cellular stress and inflammatory signals in the pathogenesis of tubulointerstitial kidney disease due to UMOD mutations. *Sci Rep*. 2017;7:7383. https://doi.org/10.1038/s41598-017-07804-6

48. Edwards N, Olinger E, Adam J, et al. A novel homozygous UMOD mutation reveals gene dosage effects on uromodulin processing and urinary excretion. *Nephrol Dial Transplant*. 2017;32:1994–1999. https://doi.org/10.1093/ndt/gfx066
49. Dvela-Levitt M, Kost-Alimova M, Emani M, et al. Small molecule targets TME9D and promotes lysosomal degradation to reverse Proteinopathy. *Cell*. 2019;178:521–535.e23. https://doi.org/10.1016/j.cell.2019.07.002

50. Bleyer AJ, Knoch S, Antignac C, et al. Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1. *Clin J Am Soc Nephrol*. 2014;9:527–535. https://doi.org/10.2215/CJN.06380613

51. Ekici AB, Hackenbeck T, Morinière V, et al. Renal fibrosis is the common feature of autosomal dominant tubulointerstitial kidney diseases caused by mutations in mucin 1 or uromodulin. *Kidney Int*. 2014;86:589–599. https://doi.org/10.1016/j.kint.2014.72

52. Blumenstiel B, Dfelice M, Birox O, et al. Development and validation of a mass spectrometry–based assay for the molecular diagnosis of mucin-1 kidney disease. *J Mol Diagn*. 2016;18:566–571. https://doi.org/10.1016/j.jmoldx.2016.03.003

53. Wenzel A, Altmueller J, Ekici AB, et al. Single molecule real time sequencing in ADTKD-MUC1 allows complete assembly of the VNTR and exact positioning of causative mutations. *Sci Rep*. 2018;8:1–12. https://doi.org/10.1038/s41598-018-22428-0

54. Knaup K, Hackenbeck T, Popp B, et al. Biallelic expression of Mucin-1 in autosomal dominant tubulointerstitial kidney disease: implications for nongenetic disease recognition. *J Am Soc Nephrol*. 2018;29:2298–2309. https://doi.org/10.1681 ASN.JASN.2018030245

55. Živná M, Kidd K, Pristoupilová A, et al. Noninvasive immunohistochemical diagnosis and novel MUC1 mutations causing autosomal dominant tubulointerstitial kidney disease. *J Am Soc Nephrol*. 2018;29:2418–2431. https://doi.org/10.1681 ASN.JASN.2018020180

56. Al-bataineh M, Sutton TA, Hughey RP. Novel roles for mucin 1 in the kidney. *Curr Opin Nephrol Hypertens*. 2017;26:384–391. https://doi.org/10.1097/MNH.0000000000000350

57. Yu SMW, Bleyer AJ, Anis K, et al. Autosomal dominant tubulointerstitial kidney disease due to MUC1 mutation. *Am J Kidney Dis*. 2018;71:495–500. https://doi.org/10.1053/ajkd.2017.08.024

58. Spicer AP, Rowse GJ, Lidner TK, Gendler SJ. Delayed mammary tumor progression in Muc-1 null mice. *J Biol Chem*. 1995;270:30093–30101. https://doi.org/10.1074/jbc.270.30093

59. Knocc S, Živná M, Bleyer AJ. Autosomal dominant tubulointerstitial kidney disease, REN-related. Source GeneReviews® [Internet]. Seattle, WA: University of Washington: Seattle; 2017.

60. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. *Physiol Rev*. 2006;86:747–803. https://doi.org/10.1152/physrev.00036.2005

61. Živná M, Kidd K, Zaidan M, et al. An international cohort study of autosomal dominant tubulointerstitial kidney disease due to REN mutations identifies distinct clinical subtypes. *Kidney Int*. 2020;98:1589–1604. https://doi.org/10.1016/j.kint.2020.06.041

62. Schaeffer C, Izi C, Vettori A, et al. Autosomal dominant tubulointerstitial kidney disease with adult onset due to a novel renin mutation mapping in the mature protein. *Sci Rep*. 2019;9:1–11. https://doi.org/10.1038/s41598-019-48014-6

63. Gribouval O, Gonzales M, Neuhaus T, et al. Mutations in the renin-angiotensin system are associated with autosomal recessive renal tubular dysgenesis. *Nat Genet*. 2005;37:964–968. https://doi.org/10.1038/ng1623

64. Bleyer AJ, Živná M, Hulková H, et al. Clinical and molecular characterization of a family with a dominant renin gene mutation and response to treatment with fludrocortisone. *Clin Nephrol*. 2010;74:411–422. https://doi.org/10.5414/cnp74411

65. Horikawa Y, Iwasaki N, Hara M, et al. Mutation in hepatocyte nuclear factor–1β gene (TCF2) associated with MODY. *Nat Genet*. 1997;17:384–385. https://doi.org/10.1038/ng1297-384

66. Bingham C, Bulman MP, Ellard S, et al. Mutations in the hepatocyte nuclear factor-1β gene are associated with familial hypoplastic glomerulocystic kidney disease. *Am J Hum Genet*. 2001;68:219–224. https://doi.org/10.1086/316945

67. Faguer S, Decramer S, Chassaing N, et al. Diagnosis, management, and prognosis of HNF1β nephropathy in adulthood. *Kidney Int*. 2011;80:768–776. https://doi.org/10.1038/ki.2011.225

68. Clissold RL, Hamilton AJ, Hattersley AT, Ellard S, Bingham C. HNF1β-associated renal and extra-renal disease—an expanding clinical spectrum. *Nat Rev Nephrol*. 2015;11:102–112. https://doi.org/10.1038/nrneph.2014.232

69. Izzi C, Dordoni C, Economo L, et al. Variable expressivity of HNF1β nephropathy, from renal cysts and diabetes to medullary sponge kidney through tubulo-interstitial kidney disease. *Kidney Int Rep*. 2020;5:2341–2350. https://doi.org/10.1016/j.ekir.2020.09.042

70. Heidet L, Decramer S, Pawtowski A, et al. Spectrum of HNF1β mutations in a large cohort of patients who harbor renal diseases. *Clin J Am Soc Nephrol*. 2010;5:1079–1090. https://doi.org/10.2215/CJN.08810809, 71.

71. Bleyer AJ, Wolf MT, Kidd KO, et al. Autosomal dominant tubulointerstitial kidney disease: more than just HNF1β. *Pediatr Nephrol*. 2021;37:933–946. https://doi.org/10.1007/s00467-021-05118-4

72. Hiesberger T, Bai Y, Shao X, et al. Mutation of hepatocyte nuclear factor–1β inhibits Pkhd1 gene expression and produces renal cysts in mice. *J Clin Invest*. 2004;113:814–825. https://doi.org/10.1172/JCI20083

73. Chan SC, Zhang Y, Shao A, et al. Mechanism of fibrosis in HNF1B-related autosomal dominant tubulointerstitial kidney disease. *J Am Soc Nephrol*. 2018;29:2493–2509. https://doi.org/10.1681 ASN.JASN.2018040437

74. Carew RM, Wang B, Kantharidis P. The role of EMT in renal fibrosis. *Cell Tissue Res*. 2012;347:103–116. https://doi.org/10.1007/s00441-011-1227-1

75. Schubert D, Klein MC, Hadsdenteufel S, et al. Plasma cell deficiency in human subjects with heterozygous mutations in Sec61 translocon alpha 1 subunit (SEC61A1). *J Allergy Clin Immunol*. 2018;141:1427–1438. https://doi.org/10.1016/j.jaci.2017.06.042

76. Lang S, Pfeffer S, Lee PH, et al. An update on Sec61 channel transport defect of the Sec61 translocon alpha 1 subunit (SEC61A1). *J Allergy Clin Immunol*. 2018;141:1427–1438. https://doi.org/10.1016/j.jaci.2017.06.042

77. Sicking M, Živná M, Bhadra P, et al. Phenylbutyrate rescues the transport defect of the Sec61α mutations V67G and T185A for renin. *Life Sci Alliance*. 2022;5:e202101150. https://doi.org/10.26508/lsa.202101150

78. Cornec-Le Gall E, Olson RJ, Besse W, et al. Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. *Am J Hum Genet*. 2018;102:832–844. https://doi.org/10.1016/j.ajhg.2018.03.013